Theravance Bio Ord (TBPH) Stock Price, Quote & News

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic co...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 808 6000

Website: www.theravance.com

Address:

901 Gateway Boulevard, South San Francisco, United States

ZacksResearch Feb. 24 at 2:18 PM

$CRMD plummets 48.9% in 6 months — Is it facing challenges in growth strategy? While CRMD's DefenCath is FDA-approved, their conservative revenue outlook for 2026 and reliance on a single product create significant risk. In contrast, $TBPH, benefiting from its Viatris collaboration and a $225M cash boost, has rallied 39.8% and offers a more balanced growth path. Compare the small-cap biotech plays here 👉 https://www.zacks.com/stock/news/2874060/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-bet?cid=sm-stocktwits-2-2874060-body-34831&ADID=SYND_STOCKTWITS_TWEET_2_2874060_BODY_34831

1 · Reply

ZacksResearch Feb. 24 at 12:07 PM

$CRMD or $TBPH — sales traction or pipeline promise? CorMedix is leaning on actual sales momentum, while Theravance is banking on future pipeline upside. Two very different growth paths in the small-cap biotech space — and very different risk profiles. Which setup gives you the better risk/reward right now? Full comparison here 👉 https://www.zacks.com/stock/news/2874060/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-bet?cid=sm-stocktwits-2-2874060-teaser-34783&ADID=SYND_STOCKTWITS_TWEET_2_2874060_TEASER_34783

0 · Reply

OfficialStocktwitsUser Feb. 19 at 12:16 PM

$TBPH RSI: 51.28, MACD: 0.0009 Vol: 0.53, MA20: 19.67, MA50: 19.11 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OfficialStocktwitsUser Feb. 19 at 1:28 AM

0 · Reply

OptionRunners Feb. 17 at 8:24 PM

$TBPH bull seagulls opening for a $4.30 credit

0 · Reply

Estimize Feb. 12 at 9:03 PM

Wall St is expecting -0.06 EPS for $TBPH Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_c

0 · Reply

BillionerOfKing Feb. 5 at 10:09 PM

$TBPH Current Stock Price: $19.57 Contracts to trade: $20.0 TBPH Feb 20 2026 Call Entry: $0.50 Exit: $0.77 ROI: 54% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

NVDAMillionaire Feb. 4 at 5:01 PM

$TBPH Really good write-up that perfectly summarizes TBPH's present situation. So if you want to bring your TBPH knowledge up to date or just discover TBPH, this is required reading. https://everyticker.com/quote/TBPH/analysis/theravance-biopharma-unlocking-value-at-a-pivotal-inflection-point-nasdaq-tbph

0 · Reply

PortfolioSentinel Feb. 4 at 3:08 PM

$TBPH is a commercial-stage biotech with a drug for pulmonary arterial hypertension; it operates in a competitive market and faces the challenge of driving market share gains.

0 · Reply

Fugazi_ Jan. 10 at 4:47 AM

$TBPH p3 data between now and March?

1 · Reply

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Nov 20, 2025, 11:00 AM EST - 3 months ago

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Nov 19, 2025, 6:00 AM EST - 3 months ago

Theravance Biopharma to Participate in Upcoming Investor Conferences

Nov 11, 2025, 4:04 AM EST - 3 months ago

Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 3 months ago

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Oct 27, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Oct 16, 2025, 8:05 AM EDT - 4 months ago

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Oct 14, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Sep 2, 2025, 6:00 AM EDT - 6 months ago

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 6:00 AM EDT - 6 months ago

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Aug 12, 2025, 6:52 PM EDT - 7 months ago

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 28, 2025, 6:00 AM EDT - 7 months ago

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 23, 2025, 6:00 AM EDT - 7 months ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

Jun 26, 2025, 6:00 AM EDT - 8 months ago

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Jun 2, 2025, 6:00 AM EDT - 9 months ago

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

GSK

May 10, 2025, 4:35 PM EDT - 10 months ago

Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:00 PM EDT - 10 months ago

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025, 4:05 PM EDT - 10 months ago

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 6:00 AM EDT - 10 months ago

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Apr 24, 2025, 6:00 AM EDT - 11 months ago

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 7, 2025, 3:55 PM EDT - 11 months ago

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Feb 26, 2025, 8:58 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 6:00 AM EST - 1 year ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Dec 17, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Nov 12, 2024, 10:46 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Oct 24, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 18, 2024, 9:00 AM EDT - 1 year ago

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Aug 5, 2024, 7:37 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

May 13, 2024, 6:58 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 10, 2024, 6:00 AM EDT - 2 years ago

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Feb 26, 2024, 9:52 PM EST - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 2 years ago

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 14, 2024, 6:00 AM EST - 2 years ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Jan 5, 2024, 6:15 AM EST - 2 years ago

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

Jan 5, 2024, 6:00 AM EST - 2 years ago

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Dec 21, 2023, 5:00 PM EST - 2 years ago

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Dec 18, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Nov 16, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Nov 15, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

VTRS

Nov 7, 2023, 11:23 PM EST - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

ZacksResearch Feb. 24 at 2:18 PM

1 · Reply

ZacksResearch Feb. 24 at 12:07 PM

0 · Reply

OfficialStocktwitsUser Feb. 19 at 12:16 PM

0 · Reply

OfficialStocktwitsUser Feb. 19 at 1:28 AM

0 · Reply

OptionRunners Feb. 17 at 8:24 PM

$TBPH bull seagulls opening for a $4.30 credit

0 · Reply

Estimize Feb. 12 at 9:03 PM

Wall St is expecting -0.06 EPS for $TBPH Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_c

0 · Reply

BillionerOfKing Feb. 5 at 10:09 PM

0 · Reply

NVDAMillionaire Feb. 4 at 5:01 PM

0 · Reply

PortfolioSentinel Feb. 4 at 3:08 PM

$TBPH is a commercial-stage biotech with a drug for pulmonary arterial hypertension; it operates in a competitive market and faces the challenge of driving market share gains.

0 · Reply

Fugazi_ Jan. 10 at 4:47 AM

$TBPH p3 data between now and March?

1 · Reply

vu_jade Dec. 30 at 5:48 PM

$TBPH great technical look

0 · Reply

Merlintrader Dec. 23 at 5:55 PM

$TBPH https://www.merlintrader.com/tbph-theravance-biopharma/

0 · Reply

jdlman Dec. 17 at 11:52 PM

$TBPH good company

0 · Reply

voorbie Dec. 16 at 12:39 AM

$TBPH Does anyone who is not a bot ever post here? It’s a graveyard. But I love this stock & would love to hear others’ thoughts.

1 · Reply

voorbie Dec. 8 at 9:23 PM

$TBPH Why the drop today?

0 · Reply

JarvisFlow Dec. 3 at 4:31 PM

Oppenheimer updates rating for Theravance Biopharma ( $TBPH ) to Outperform, target set at 27.

0 · Reply

SuperGreenToday Dec. 3 at 3:16 PM

$TBPH Share Price: $18.80 Contract Selected: Jun 18, 2026 $20 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.97 – $3.63 Potential Upside: 78% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Dec. 3 at 11:34 AM

Oppenheimer🏁 $TBPH Outperform/$27 $VTRS $HLUBF $HLBBF TAK $GSK AZN Oppenheimer said, We are launching on Theravance Biopharma at Outperform with a $27 PT. We see potential for the company's 1Q26 Phase 3 ampreloxetine readout to be transformative with a positive risk/reward into topline data. Our 50% PoS supports ~50% upside potential, and approval would likely support a roughly doubling of our valuation expectations. Downside risk is offset with Yupelri supporting the company at near cash flow breakeven, along with an anticipated pro forma cash balance after royalty milestones of ~$500M. Theravance shares have bid up over the past month (+26% vs. XBI's +5%) into Phase 3 data as we believe investors are taking notice of the transformative potential and mechanistic rationale, along with the downside protection. Positive Phase 3 data would likely support positive re-rating with $1B+ sales potential.

0 · Reply

BioSpecialOne Dec. 3 at 9:23 AM

$TBPH Eran Broshy, a 10% owner and director of Theravance Biopharma, sold a total of 29,501 ordinary shares on November 26, 2025, at a price of $20.0 per share, resulting in a total sale amount of $590,020. Following these transactions, Broshy directly owns 44,703 ordinary shares of the company.

0 · Reply

Estimize Dec. 2 at 9:00 PM

Wall St is expecting 1.00 EPS for $TBPH Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_co

0 · Reply

anachartanalyst Nov. 26 at 1:02 PM

$TBPH https://anachart.com/wp-content/uploads/ana_temp/1764162091_soc-img.jpg

0 · Reply

JarvisFlow Nov. 26 at 12:10 PM

BTIG has adjusted their stance on Theravance Biopharma ( $TBPH ), setting the rating to Buy with a target price of 25 → 40.

0 · Reply

Market Cap	924.76M
Revenue (ttm)	64.38M
Net Income (ttm)	-56.42M
EPS (ttm)	N/A
PE Ratio	38.83
Forward PE	N/A
Profit Margin	-87.64%
Debt to Equity Ratio	0.00

Volume	1,354,300
Avg Vol	455,104
Day's Range	N/A - N/A
Shares Out	50.67M
Stochastic %K	20%
Beta	0.15
Analysts	Strong Sell
Price Target	$26.71